Ayurvedic medication in the treatment of Irritable Bowel Syndrome
Phase 2
- Conditions
- Health Condition 1: K581- Irritable bowel syndrome with constipationHealth Condition 2: K580- Irritable bowel syndrome with diarrhea
- Registration Number
- CTRI/2022/12/048261
- Lead Sponsor
- Dr RAJAT THAKUR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Individuals between the age group of 20 to 60 years
patients of either sex
subjects fulfilling the diagnostic Rome 4 criteria
Exclusion Criteria
Other subtypes of IBS like mixed and unclassified
Diagnosed with Inflammatory bowel disorders
Known case of CA colon, Intestinal tuberculosis
Patients with chronic alcoholism
Patients with any co-morbidities needs long term drug treatment, rheumatoid arthritis, tuberculosis, uncontrolled diabetes, HTN, etc.
Pregnant or lactating women .
Patient have an allergic reaction to Mebeverine in the past.
Patients on any medications for the management of IBS in the last 30 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IBS Adequate Relief <br/ ><br>IBS symptom severity scoreTimepoint: 60 days
- Secondary Outcome Measures
Name Time Method Gastrointestinal Symptom Rating Scale (GSRS) IBS –Visual Analogue Scale (IBS-VAS) Complete Spontaneous Bowel Movements (CSBMs) Bristol Stool Form (BSF) Hamilton Anxiety Rating scale Hamilton Depression Rating scale IBS quality of life (IBS–Qol) <br/ ><br>Stool Examination, Interleukin -6 (IL-6) <br/ ><br>Timepoint: <br/ ><br>GSRS,IBS-VAS,CSBMs,BSF, Hamilton Anxiety Rating scale ,Hamilton Depression Rating scale & IBS-Qol on baseline 15th 30th 45th 60th day . Stool Examination & Interleukin 6 on baseline & 60th day <br/ ><br>